Essential Biomarkers & Genetic Alterations Evaluated
Precision oncology requires rigorous verification of somatic mutations, protein expression, and genomic signatures before finalizing a treatment protocol.
MSI-H / dMMR (Mismatch Repair Deficiency)
Confers extraordinary responsiveness to frontline immunotherapy (Pembrolizumab / Nivolumab+Ipilimumab), often eliminating chemotherapy.
Extended RAS (KRAS / NRAS Exons 2, 3, 4)
Mutations predict resistance to anti-EGFR therapies (Cetuximab, Panitumumab); wild-type status is mandatory for EGFR inhibitor efficacy.
BRAF V600E Mutation
Defines an aggressive sub-phenotype requiring triplet targeted therapy (Encorafenib + Cetuximab) rather than standard chemo.
HER2 Amplification (IHC/FISH/NGS)
Identifies a subset of RAS wild-type tumors responsive to dual HER2 blockade (Trastuzumab + Tucatinib).
Circulating Tumor DNA (Signatera / Guardant Reveal)
Detects molecular residual disease (MRD) after Stage II/III surgery to guide adjuvant chemotherapy escalation or de-escalation.
Critical Treatment Decisions Addressed in Your Review
Our multidisciplinary panel examines your case from medical oncology, surgical, and radiation oncology angles to address these pivotal questions:
Resectability of Colorectal Liver Metastases (CRLM)
Multidisciplinary surgical review evaluating portal vein embolization, staged hepatectomies, and hepatic arterial infusion (HAI) pumps.
Total Neoadjuvant Therapy (TNT) for Rectal Cancer
Preoperative chemotherapy and chemoradiation to achieve clinical complete response and avoid permanent colostomy.
Adjuvant Chemotherapy in Stage II Colon Cancer
Balancing high-risk features (T4, <12 lymph nodes, bowel obstruction) and ctDNA MRD status to avoid unnecessary toxic FOLFOX/CAPOX.
Left-Sided vs Right-Sided Primary Selection
Left-sided RAS wild-type tumors derive superior benefit from anti-EGFR, whereas right-sided tumors favor anti-VEGF (Bevacizumab).
Records Required for Colorectal Cancer Second Opinion
Upload your files online. Our team coordinates directly with your hospital if records are incomplete.
Pathology & Biopsy Reports
Complete histopathology, tumor margin documentation, and formal IHC score sheets.
Raw DICOM Scans
CT, MRI, PET-CT discs or digital cloud download links (not just radiologist text summaries).
Genomic & NGS Panels
FoundationOne, Guardant, Tempus, or specialized assay reports (e.g. Oncotype, Decipher).
Frequently Asked Questions: Colorectal Cancer
Clear clinical answers regarding diagnostic accuracy, surgical options, and biomarker interpretation.
Related Second Opinion & Diagnostic Services
Cancer decisions intersect pathology, radiology, and adjacent disease subspecialties.
Cancer Pathology Second Opinion
Pathology is the foundational blueprint of every cancer diagnosis, yet it is inherently interpretive. Major peer-reviewed medical studies document that 15% to 30% of second-look pathology reviews uncover diagnostic discordance: benign conditions mistaken for malignant tumors, incorrect tumor staging, missed lymphovascular invasion, or discordant hormone receptor/HER2 status that profoundly alters systemic treatment.
Cancer Radiology Second Opinion
Radiology reports are often produced under high-volume general hospital conditions where subtle oncologic nuances can be overlooked. Up to 20% of expert radiology second opinions identify critical discrepancies: unrecognized liver or peritoneal metastases, missed vascular encasement that alters surgical resectability, or confusion between treatment-induced pseudo-progression and true tumor growth.
Prostate Cancer Second Opinion
Prostate cancer is characterized by widespread overtreatment of indolent tumors and undertreatment of aggressive variants. Central pathology re-evaluation modifies the assigned Gleason score or ISUP Grade Group in up to 25% of cases. A second opinion integrates multiparametric MRI (PI-RADS v2.1), Decipher / Prolaris genomic testing, and PSMA PET-CT to determine whether active surveillance, robotic prostatectomy, focal therapy, or SBRT is the optimal pathway.
Complete Second Opinion Guide
Compare multidisciplinary reviews, read about record transfer logistics, and review transparent $450 flat pricing.
Get an Independent Second Opinion on Your Colorectal Cancer Diagnosis
Upload your biopsy pathology slides, NGS reports, and DICOM scans. Receive a comprehensive multidisciplinary written report and staging audit within 12 to 72 hours.